« Back
Praziquantel lipid nanocapsules: An oral nanotherapeutic for potential schistosoma mansoni targeting
Poster Title: Praziquantel lipid nanocapsules: An oral nanotherapeutic for potential schistosoma mansoni targeting
Submitted on 05 Nov 2022
Author(s): Rokaya O Amara,1,2 Alyaa A Ramadan,1 Riham M El-Moslemany,1 Maha M Eissa,3 Mervat Z El-Azzouni,3 and Labiba K El-Khordagui1
Affiliations: 1Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt, ge.ude.uxela@nadamar.aayla 2Biotechnology Research Center, Tripoli, Libya 3Department of Medical Parasitology, Faculty of Medicine, Alexandria University, Alexandria, Egypt Correspondence: Alyaa A Ramadan, Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, 1 Khartoum Square, Azarita, Alexandria 21521, Egypt, Tel +20 12 2115 1295, Fax +20 3 487 3273, Email ge.ude.uxela@nadamar.aayla
This poster was presented at Conference: 17th Arab International Conference on Material ScienceAt: Institute of Graduate Studies and Research-Egypt
Poster Views: 296
View poster »

Poster Information
Abstract: Oral praziquantel (PZQ) is currently the exclusive treatment
of schistosomiasis. Despite efficacy, PZQ therapy has
several limitations, mainly poor bioavailability and short
half-life (0.8-1.5 h) which necessitates administration of a
relatively large dose[1]
. Research efforts are needed to
further enhance PZQ efficacy for dose reduction. The
objective of the present study was to develop a PZQ
nanomedicine with enhanced oral bioavailability and efficacy
using lipid nanocapsules (LNC) as nanovectors.
Summary: PZQ-LNCs proved stable in simulated GIT fluids for 6 h
• Nano-objects possibly related to PZQ-LNCs appeared on the tegument of
blood flukes providing a proof of concept for intestinal transport of native
• Lack of PK/PD correlation
Combined findings point to the dependence of activity on structural integrity
of PZQ-LNCs post oral absorption
Thus, PZQ-LNCs may present oral targeted nanovectors for effective
antischistosomal therapy in a reduced dose.
In v
References: 1. Olliaro, P., Delgado-romero, P. & Keiser, J. 2014. The little we know about the
pharmacokinetics and pharmacodynamics of praziquantel. Journal of
Antimicrobial Chemotherapy, 69, 863-870.
2. Heurtault B,et al., (2002) A novel phase inversion-based process for the
preparation of lipid nanocarriers. Pharm Res 19(6): 875-880.
3. Roger E, Lagarce F, Benoit JP (2009) The gastrointestinal stability of lipid
nanocapsules. Int J Pharm 379(2): 260-265.
4. Eissa, M. M., El-moslemany, R. M., Ramadan. A.A., Amer, E. I., El-azzouni,
M. Z. & El-khordagui, L. K. 2015b. Miltefosine Lipid Nanocapsules for Single
Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study. PLoS
One, 10, e0141788.
Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Tofacitinib Citrate

Different Cell Separation Strategies
Richard J. Gray

Abstract 23: Precision medicine approaches to Fanconi anemia oral cancer personalized prevention and treatment
Daniel K. Swenson; Beverly R. Wuertz; Mustafa M. Ali; Gretchen M. Unger; Frank G. Ondrey

Genomic analysis points to changes in markers of stemness in oral cancer progression
Gretchen M. Unger, Beverly R. Wuertz, Patrick M. Gaffney, Frank G. Ondrey.

Potential chemopreventive treatments in Fanconi anemia related oral squamous carcinoma
Kimberly A Miller, Beverly R Wuertz, Anna Haynes, David A Potter, and Frank G Ondrey